SG11201909562PA - Treatment of a bacterial vaginal infection - Google Patents

Treatment of a bacterial vaginal infection

Info

Publication number
SG11201909562PA
SG11201909562PA SG11201909562PA SG11201909562PA SG 11201909562P A SG11201909562P A SG 11201909562PA SG 11201909562P A SG11201909562P A SG 11201909562PA SG 11201909562P A SG11201909562P A SG 11201909562PA
Authority
SG
Singapore
Prior art keywords
international
vaginal infection
pct
treatment
rule
Prior art date
Application number
Other languages
English (en)
Inventor
Sylwia Berdzik-Kalarus
Daniel Sulikowski
Original Assignee
Adamed Pharma S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adamed Pharma S A filed Critical Adamed Pharma S A
Publication of SG11201909562PA publication Critical patent/SG11201909562PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG11201909562P 2017-04-14 2018-04-03 Treatment of a bacterial vaginal infection SG11201909562PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17461524.5A EP3388063A1 (en) 2017-04-14 2017-04-14 Treatment of a bacterial vaginal infection
PCT/EP2018/058508 WO2018188992A1 (en) 2017-04-14 2018-04-03 Treatment of a bacterial vaginal infection

Publications (1)

Publication Number Publication Date
SG11201909562PA true SG11201909562PA (en) 2019-11-28

Family

ID=58578922

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201909562P SG11201909562PA (en) 2017-04-14 2018-04-03 Treatment of a bacterial vaginal infection

Country Status (18)

Country Link
US (2) US11684608B2 (es)
EP (2) EP3388063A1 (es)
BR (1) BR112019021404A2 (es)
CO (1) CO2019011305A2 (es)
CR (1) CR20190466A (es)
DK (1) DK3609493T3 (es)
EA (1) EA201992448A1 (es)
ES (1) ES2984250T3 (es)
FI (1) FI3609493T3 (es)
LT (1) LT3609493T (es)
MX (1) MX2019012232A (es)
MY (1) MY196293A (es)
PH (1) PH12019502332A1 (es)
PL (1) PL3609493T3 (es)
PT (1) PT3609493T (es)
RS (1) RS65819B1 (es)
SG (1) SG11201909562PA (es)
WO (1) WO2018188992A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3388063A1 (en) * 2017-04-14 2018-10-17 Adamed sp. z o.o. Treatment of a bacterial vaginal infection
US11529346B2 (en) * 2020-06-18 2022-12-20 National Medical Supply, LLC Vaginal gel

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500516A (en) * 1982-10-22 1985-02-19 Institut Organicheskogo Sinteza Akademii Nauk Latviiskoi Ssr Antibacterial pharmaceutical composition
US4542020A (en) * 1984-08-17 1985-09-17 E. R. Squibb & Sons, Inc. Long-lasting adhesive antifungal suppositories
CA2008775C (en) 1989-02-24 1998-12-22 Alberto Ferro Nail lacquer
WO2002014493A2 (en) * 2000-08-11 2002-02-21 Whitehead Institute For Biomedical Research Control of biofilm development
JP2004067599A (ja) * 2002-08-07 2004-03-04 Kunihiko Tominaga 腟内洗浄剤
WO2012106264A2 (en) * 2011-01-31 2012-08-09 The Trustees Of Columbia University In The City Of New York Treatment and prevention of bacterial vaginosis and gardnerella vaginalis infections
EP3388063A1 (en) 2017-04-14 2018-10-17 Adamed sp. z o.o. Treatment of a bacterial vaginal infection

Also Published As

Publication number Publication date
ES2984250T3 (es) 2024-10-29
EP3609493B1 (en) 2024-05-15
EP3388063A1 (en) 2018-10-17
BR112019021404A2 (pt) 2020-04-28
PL3609493T3 (pl) 2024-09-02
EA201992448A1 (ru) 2020-02-17
WO2018188992A1 (en) 2018-10-18
US20200078337A1 (en) 2020-03-12
EP3609493A1 (en) 2020-02-19
RS65819B1 (sr) 2024-09-30
CO2019011305A2 (es) 2019-10-31
LT3609493T (lt) 2024-08-26
US11684608B2 (en) 2023-06-27
PH12019502332A1 (en) 2020-10-12
PT3609493T (pt) 2024-08-14
US20230270725A1 (en) 2023-08-31
MX2019012232A (es) 2019-11-28
MY196293A (en) 2023-03-24
DK3609493T3 (da) 2024-08-05
FI3609493T3 (fi) 2024-08-13
CR20190466A (es) 2019-11-15

Similar Documents

Publication Publication Date Title
SG11201907034PA (en) Methods of treating influenza
SG11201908971RA (en) Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201907604UA (en) Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan
SG11201906431UA (en) Method for the treatment of thromboembolism
SG11202000266VA (en) Quinoline derivatives for treating infections with helminths
SG11201807913XA (en) Stabilized soluble pre-fusion rsv f proteins
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201810177VA (en) Pet-imaging immunomodulators
SG11201804263PA (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201906222WA (en) Jak1 selective inhibitors
SG11201901534VA (en) Combination therapy with controlled-release cnp agonists
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201900021PA (en) Methods and compositions for the treatment of cancer
SG11201906959RA (en) Aryl hydrocarbon receptor (ahr) modulator compounds
SG11201809341PA (en) Mobile robot
SG11201810078PA (en) Stabilized pre-fusion rsv f proteins
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201808686VA (en) Synthesis of indazoles
SG11201805001UA (en) Method of treating influenza a
SG11201803643TA (en) Virulence attenuated bacteria for treatment of malignant solid tumors
SG11201810801QA (en) Brain delivery protein
SG11201408509PA (en) Racecadotril lipid compositions
SG11201806393QA (en) Use of gabaa receptor modulators for treatment of itch